An update to monoclonal antibody as therapeutic option against COVID-19.
An update to monoclonal antibody as therapeutic option against COVID-19.
复制标题
DOI：
10.1016/j.bsheal.2021.02.001
复制
发表时间：
2021-04
影响因子：
--
通讯作者：
Saif-Ur-Rahman KM
中科院分区：
文献类型：
--
作者：
Deb P;Molla MMA;Saif-Ur-Rahman KM
随着全球 2019 冠状病毒病 (COVID-19) 病例数量激增，而大多数国家普通人群的疫苗供应有限，单克隆抗体 (mAb) 仍然是治疗 COVID-19 疾病及其并发症的可行治疗选择，特别是对于老年人。全球不同国家正在进行50多项单克隆抗体相关临床试验，其中很少有接近完成三期和四期临床试验的项目。鉴于最近 FDA（食品和药物管理局）对 casirivimab 和 imdevimab 进行了紧急使用授权 (EUA)，科学界对已用于治疗埃博拉和呼吸道合胞病毒 (RSV) 感染等疾病的单克隆抗体进行讨论具有重要意义。这篇简短的综述讨论了用于治疗 COVID-19 的不同单克隆抗体的作用机制和临床试验的更新，特别关注宿主细胞中的 SARS-CoV-2 免疫反应、目标病毒结构，以及在不同国家的脆弱人群中批准和使用潜在有效疫苗后开发单克隆抗体的理由。
With the number of Coronavirus Disease 2019 (COVID-19) cases soaring worldwide and limited vaccine availability for the general population in most countries, the monoclonal antibody (mAb) remains a viable therapeutic option to treat COVID-19 disease and its complications, especially in the elderly individuals. More than 50 monoclonal antibody-related clinical trials are being conducted in different countries around the world, with few of them nearing the completion of the third and fourth phase clinical trial. In view of recent emergency use authorization (EUA) from the FDA (Food and Drug Administration) of casirivimab and imdevimab, it is of importance that mAbs, already used to treat diseases such as Ebola and respiratory syncytial virus (RSV) infection, are discussed in scientific communities. This brief review discusses the mechanism of action and updates to clinical trials of different monoclonal antibodies used to treat COVID-19, with special attention paid to SARS-CoV-2 immune response in host cells, target viral structures, and justification of developing mAbs following the approval and administration of potential effective vaccine among vulnerable populations in different countries.
登录
查看更多内容
影响因子：
25.4
作者：
Guaraldi, Giovanni;Meschiari, Marianna;Mussini, Cristina
通讯作者：
Mussini, Cristina
DOI：
10.1056/nejmoa2029849
发表时间：
2021-01-21
期刊：
The New England journal of medicine
影响因子：
--
作者：
Chen P;Nirula A;Heller B;Gottlieb RL;Boscia J;Morris J;Huhn G;Cardona J;Mocherla B;Stosor V;Shawa I;Adams AC;Van Naarden J;Custer KL;Shen L;Durante M;Oakley G;Schade AE;Sabo J;Patel DR;Klekotka P;Skovronsky DM;BLAZE-1 Investigators
通讯作者：
BLAZE-1 Investigators
影响因子：
4.4
作者：
Yu XF;Liang LH;She M;Liao XL;Gu J;Li YH;Han ZC
通讯作者：
Han ZC
影响因子：
168.9
作者：
Huang, Chaolin;Wang, Yeming;Cao, Bin
通讯作者：
Cao, Bin
DOI：
10.1016/j.ijid.2020.10.101
发表时间：
2021-03
期刊：
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
影响因子：
--
作者：
Patterson BK;Seethamraju H;Dhody K;Corley MJ;Kazempour K;Lalezari J;Pang APS;Sugai C;Mahyari E;Francisco EB;Pise A;Rodrigues H;Wu HL;Webb GM;Park BS;Kelly S;Pourhassan N;Lelic A;Kdouh L;Herrera M;Hall E;Bimber BN;Plassmeyer M;Gupta R;Alpan O;O'Halloran JA;Mudd PA;Akalin E;Ndhlovu LC;Sacha JB
通讯作者：
Sacha JB